Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $151

Benzinga · 3d ago
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $119 to $151.